Court limits Canada’s power over generic drug prices

Canadian generics


A federal court in Canada has agreed with the industry that the country’s price setting board has assumed too much authority and severely curtailed its ability to control prices over generic drugs in a case centered on Novartis’ generic drug company Sandoz, and a unit of Teva Pharmaceutical Industries, which started as Ratiopharm. The ruling limits the Patented Medicine Prices Review Board from being able to set prices for generic drugs, meaning that generic drug makers who don’t hold patents themselves or exercise monopoly power need not file price information with the Board.

Read the source article at Pharma News

About the Author

Leave a Reply